TVARDI THERAPEUTICS, INC. Investing Cash Flow
TVARDI THERAPEUTICS, INC. (TVRD) reported Investing Cash Flow of $10.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $5.14M.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $4.98M.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $5.00M, a 0.00% change year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $5.35M, a 113.96% increase year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$10.08M, a 120.69% decline from fiscal 2024.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $48.74M, a 12.15% increase from fiscal 2023.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $43.46M, a 66.23% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $128.71M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.12M 10-Q · filed 2026-08-14 | $15.12M derived: sum of 3 quarters · filed 2026-08-14 | $20.47M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.98M 10-Q · filed 2026-05-08 | $9.98M derived: sum of 2 quarters · filed 2026-05-08 | $15.32M derived: sum of 3 quarters · filed 2026-05-08 | $5.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $10.35M derived: sum of 2 quarters · filed 2026-03-31 | $799.00K derived: sum of 3 quarters · filed 2026-08-14 | -$10.08M 10-K · filed 2026-03-31 |
| 2025-09-30 | $5.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.20M derived: sum of 2 quarters · filed 2026-08-14 | -$15.08M 10-Q · filed 2025-11-13 | -$10.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$9.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$20.43M 10-Q · filed 2026-08-14 | -$15.43M derived: sum of 3 quarters · filed 2026-08-14 | -$12.93M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$10.88M 10-Q · filed 2026-05-08 | -$5.88M derived: sum of 2 quarters · filed 2026-05-08 | -$3.38M derived: sum of 3 quarters · filed 2026-05-08 | $11.91M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $7.50M derived: sum of 2 quarters · filed 2025-03-11 | $22.79M derived: sum of 3 quarters · filed 2025-03-11 | $48.74M 10-K · filed 2025-03-11 |
| 2024-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $17.79M derived: sum of 2 quarters · filed 2024-11-14 | $43.74M 10-Q · filed 2024-11-14 | $13.54M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $15.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $41.24M 10-Q · filed 2024-08-14 | $11.04M derived: sum of 3 quarters · filed 2025-05-13 | $34.19M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $25.95M 10-Q · filed 2025-05-13 | -$4.25M derived: sum of 2 quarters · filed 2025-05-13 | $18.90M derived: sum of 3 quarters · filed 2025-05-13 | $51.70M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$30.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$7.05M derived: sum of 2 quarters · filed 2025-03-11 | $25.75M derived: sum of 3 quarters · filed 2025-03-11 | $43.46M 10-K · filed 2025-03-11 |
| 2023-09-30 | $23.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $55.96M derived: sum of 2 quarters · filed 2024-11-14 | $73.67M 10-Q · filed 2024-11-14 | $118.09M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $32.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $50.51M 10-Q · filed 2024-08-14 | $94.93M derived: sum of 3 quarters · filed 2025-03-11 | $116.11M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $17.71M 10-Q · filed 2024-05-13 | $62.13M derived: sum of 2 quarters · filed 2025-03-11 | $83.31M derived: sum of 3 quarters · filed 2025-03-11 | $112.98M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $44.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $65.60M derived: sum of 2 quarters · filed 2025-03-11 | $95.28M derived: sum of 3 quarters · filed 2025-03-11 | $128.71M 10-K · filed 2025-03-11 |
| 2022-09-30 | $21.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $50.85M derived: sum of 2 quarters · filed 2023-11-13 | $84.28M 10-Q · filed 2023-11-13 | $30.70M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $29.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $63.11M 10-Q · filed 2023-08-07 | $9.53M derived: sum of 3 quarters · filed 2024-03-06 | $23.96M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $33.43M 10-Q · filed 2023-05-15 | -$20.15M derived: sum of 2 quarters · filed 2024-03-06 | -$5.72M derived: sum of 3 quarters · filed 2024-03-06 | $14.81M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$53.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$39.15M derived: sum of 2 quarters · filed 2024-03-06 | -$18.62M derived: sum of 3 quarters · filed 2024-03-06 | -$4.75M 10-K · filed 2024-03-06 |
| 2021-09-30 | $14.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $34.96M derived: sum of 2 quarters · filed 2022-11-07 | $48.83M 10-Q · filed 2022-11-07 | -$115.33M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $20.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $34.40M 10-Q · filed 2022-08-08 | -$129.76M derived: sum of 3 quarters · filed 2023-03-06 | -$90.22M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $13.87M 10-Q · filed 2022-05-09 | -$150.29M derived: sum of 2 quarters · filed 2023-03-06 | -$110.75M derived: sum of 3 quarters · filed 2023-03-06 | -$43.37M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | -$164.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$124.62M derived: sum of 2 quarters · filed 2023-03-06 | -$57.23M derived: sum of 3 quarters · filed 2023-03-06 | -$20.27M 10-K · filed 2023-03-06 |
| 2020-09-30 | $39.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $106.92M derived: sum of 2 quarters · filed 2021-11-08 | $143.88M 10-Q · filed 2021-11-08 | $158.62M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $67.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $104.34M 10-Q · filed 2021-08-09 | $119.08M derived: sum of 3 quarters · filed 2022-03-01 | $22.20M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $36.96M 10-Q · filed 2021-05-10 | $51.70M derived: sum of 2 quarters · filed 2022-03-01 | -$45.18M derived: sum of 3 quarters · filed 2022-03-01 | -$19.96M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $14.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$82.14M derived: sum of 2 quarters · filed 2022-03-01 | -$56.91M derived: sum of 3 quarters · filed 2022-03-01 | -$30.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$96.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$71.65M derived: sum of 2 quarters · filed 2020-11-09 | -$45.25M 10-Q · filed 2020-11-09 | -$103.08M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $25.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $51.63M 10-Q · filed 2020-08-10 | -$6.20M derived: sum of 3 quarters · filed 2021-02-25 | -$750.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $26.40M 10-Q · filed 2020-05-11 | -$31.43M derived: sum of 2 quarters · filed 2021-02-25 | -$25.98M derived: sum of 3 quarters · filed 2021-02-25 | -$77.11M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$57.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$52.38M derived: sum of 2 quarters · filed 2021-02-25 | -$103.51M derived: sum of 3 quarters · filed 2021-02-25 | -$82.82M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$45.68M derived: sum of 2 quarters · filed 2019-11-05 | -$24.99M 10-Q · filed 2019-11-05 | -$16.86M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$51.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$30.44M 10-Q · filed 2019-08-07 | -$22.32M derived: sum of 3 quarters · filed 2020-02-27 | -$10.24M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $20.69M 10-Q · filed 2019-05-07 | $28.82M derived: sum of 2 quarters · filed 2020-02-27 | $40.90M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $20.20M derived: sum of 2 quarters · filed 2020-02-27 | -$36.50M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $12.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$44.63M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$56.70M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $45.02M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |